Navigation Links
Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 in Adults With Chronic Genotype 1 HCV
Date:2/18/2011

patients in this trial will either receive peginterferon alfa-2a (Pegasys®) and ribavirin (Copegus®) or peginterferon alfa-2b (PegIntron®) and ribavirin (Rebetol®) as part of their treatment. A third global, phase 3, double-blind randomized study, known as TMC435-C3007 or PROMISE (PROtease inhibitor TMC435 In PatientS who have previously rElapsed on IFN/RBV), will evaluate a single TMC435 once-daily oral tablet (150 mg) verses placebo in HCV patients who experienced viral relapse after previous interferon-based therapy. Both groups will receive peginterferon alfa-2a (Pegasys®) and ribavirin (Copegus®). The complete treatment duration for all three trials will be 24 or 48 weeks, depending on patient response.

The studies will be conducted at more than 160 sites in 24 countries, including the U.S. and countries throughout Europe, and together seek to enroll approximately 1,125 HCV genotype 1 infected patients who are treatment-naive or have experienced a relapse after previous interferon-based HCV therapy. To be eligible, patients must have chronic hepatitis C infection, and must have had a liver biopsy within three years of the screening visit. For those patients who have not had a liver biopsy in the three years prior to the study, one will be performed before the baseline visit. In addition, eligible patients need to have completed a recent ultrasound with no findings suspicious of hepatocellular carcinoma (HCC). Patients with signs of hepatic decompensation, liver disease of any non-HCV etiology, co-infection with hepatitis B or HIV-1 and 2 or a history of malignancy within 5 years of the screening vitis are ineligible for the study. Patients in QUEST-1 and QUEST-2 trials must not have received any prior treatment for hepatitis C, and patients in the PROMISE trial must have previously received at least 24 weeks of (peg)interferon-based therapy, along with documented negative HCV RNA at last o
'/>"/>

SOURCE Tibotec Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
2. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
3. Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
4. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
5. Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds
6. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
7. Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS
8. Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers
9. Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
10. Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD
11. Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 1, 2014 Research and Markets ... "Global Medical Biosensors Market 2014-2018" report to ... Medical biosensors are used to ... detectors. These biosensors monitor health status, disease betterment, ... methods. They are cost-effective and user-friendly devices. Also, ...
(Date:8/1/2014)... PALO ALTO, Calif. , Aug. 1, ... (CFRI) today announced a partnership to expand awareness of ... through the CFChef Shares program. CFChef Shares will run ... of AbbVie,s CFChef program – an online resource for ... maintain a healthy diet by submitting recipes to the ...
(Date:8/1/2014)... DALLAS , August 1, 2014 ... Care Market by Type (Traditional Wound Closure, Anti infective), ... Active (Artificial Skin & Skin Substitutes), Pressure Relief ... by MarketsandMarkets, the global Wound Care Market is expected ... Billion in 2014, growing at a CAGR of ...
Breaking Medicine Technology:Global Medical Biosensors Market 2014-2018: Key Vendors are Abbott, Bayer, LifeScan and F. Hoffmann-La Roche 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3
(Date:8/1/2014)... This week marks a significant milestone ... week of paying commissions to its independent distributor sales ... January 2005 total $1,405,954,677.06. , MonaVie distributors can be ... pays commissions in 18 different currencies, including: AUD, EUR, ... PLN, USD, SGD, KRW, TWD, THB and GBP. ...
(Date:8/1/2014)... A leading dress supplier, Discount-Dress.com, explores a variety of ... any lady’s wardrobe fashionable and exciting. Recently, the company has ... To attract more people, it is now launching a special ... to 65% off. , “Summer is the season of short ... to our collection of ‘ 2014 summer short styles .’ ...
(Date:8/1/2014)... August 01, 2014 Transparency Market ... the addition of a comprehensive report on the ... System Market (Large Volume, Disposable, Syringe, Ambulatory and ... Trends And Forecast, 2013 – 2019’ is now ... http://www.transparencymarketresearch.com . , To begin with, the report ...
(Date:8/1/2014)... CentraComm, a leading managed IT security ... the Pure Storage® Authorized Reseller program. , ... experience designed to meet the rigorous resiliency, scalability, ... diverse markets, and for a variety of high ... years. , The Pure Storage FlashArray was ...
(Date:8/1/2014)... HealthDay Reporter THURSDAY, July 31, 2014 ... Africa has a well-earned reputation as one of the world,s ... intense medical care can greatly improve a person,s chances of ... wreaks life-threatening havoc within the body by attacking multiple organ ... back on the basics of "good meticulous intensive care," supporting ...
Breaking Medicine News(10 mins):Health News:MonaVie Records 500th Commission Week, Having Paid Out More Than $1.4B in Distributor Commissions 2Health News:Discount-Dress.com’s Top Trend Report: 2014 Summer Short Bridesmaid Dresses Now for Sale 2Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 2Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 3Health News:CentraComm Accepts Pure Storage Authorized Reseller Partner Invitation 2Health News:CentraComm Accepts Pure Storage Authorized Reseller Partner Invitation 3Health News:There's No Ebola Cure, But Early Intensive Treatment Boosts Survival 2Health News:There's No Ebola Cure, But Early Intensive Treatment Boosts Survival 3
... Lifeclinic International is this year,s Gold Sponsor of the Harvard Business ... Joseph B. Martin Conference Center, Harvard Medical School, November 6 - ... ... 2008 -- Lifeclinic International, Inc. , the world,s leading manufacturer ...
... Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today ... On Tuesday, November 11, 2008 at 2:50 p.m. ... a corporate presentation at the,Rodman & Renshaw 10th Annual ... November 12, 2008 at 3:30 p.m. MST (5:30 p.m. ...
... Product Will Be Sold by A Uniquely-Trained Sales ... ... Group plc,(LSE: PSK) today announced that SANCUSO(R) (Granisetron Transdermal System),is now available ... States. Sancuso was approved by,the U.S. Food and Drug Administration (F.D.A.) in ...
... have vaccination rates far below goals, study finds , , ... adolescents with asthma and other high-risk illnesses are getting ... vaccination rates from 1992 to 2002 for 18,703 adolescents ... conditions. , During the study period, vaccination rates improved, ...
... Fifteen Abstracts Will Be Featured at ASN, ... a leading,provider of kidney care services for those ... DaVita Clinical Research(R) (DCR),recently contributed fifteen abstracts to ... American Society of Nephrology. These,abstracts were developed both ...
... Nov. 4 The Quantum Group,Inc. (Amex: ... today that Noel J. Guillama, President & Chief ... Annual Westergaard,Conference on November 12, 2008. Mr. Guillama ... and Chief Technology & Innovations Officer,and Ron Smith, ...
Cached Medicine News:Health News:Lifeclinic International Lead Sponsor at Harvard Business School Health Conference 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 3Health News:Too Many High-Risk Teens Not Getting Flu Shots 2Health News:DaVita Abstracts Accepted into American Society of Nephrology Meeting 2Health News:DaVita Abstracts Accepted into American Society of Nephrology Meeting 3Health News:DaVita Abstracts Accepted into American Society of Nephrology Meeting 4Health News:The Quantum Group Inc. To Present at Paulson Investment's 31st Annual Westergaard Conference 2Health News:The Quantum Group Inc. To Present at Paulson Investment's 31st Annual Westergaard Conference 3
Ballard trach care HMES and filters, tv 1500, HME with built-in flex tube...
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
... The Portex® Thermovent® T helps provide protection to ... is small and extremely lightweight making it ideal ... With a high rate of heat and moisture ... retention., ,All HMEs and filters have ISO ...
... helps provide protection to the exposed airway of ... lightweight making it ideal for active young children ... of heat and moisture recovery, it ensures patient ... and filters have ISO standard tapered ends to ...
Medicine Products: